Is Glaxo's niche-drug strategy a sleeper?

GlaxoSmithKline CEO Andrew Witty (photo) answers a U.K. broadcaster's question: If Glaxo isn't going to develop blockbuster meds, then who is? It doesn't impress PharmaGossip, which proposes the broadcast as a preternaturally effective insomnia treatment. (Video) Report | Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.